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Introduction
Eosinophils are terminally differentiated granulocytes that devel-
op in the BM under the control of key transcription factors, mainly 
GATA1, C/EBPα, PU.1, and XBP1 (1–6). They are characterized by 
the presence in their cytoplasm of specific secondary granules con-
taining toxic cationic proteins, which are stainable with acid aniline 
dyes and Congo red (1, 7). Eosinophil granules contain a crystalloid 
core made of major basic proteins 1 and 2 (MBP1 and MBP2) and a 
matrix composed of eosinophil cationic protein, eosinophil peroxi-
dase (EPO), and eosinophil-derived neurotoxin (1).
Under physiological conditions, only small numbers of eosin-
ophils are released from the BM. By contrast, eosinophilopoiesis is 
dramatically increased as a result of Th2 cell responses associated 
with helminth infections or allergic diseases such as asthma (1, 2, 8). 
This increase in eosinophil production is driven by a dedicated set 
of cytokines, namely IL-3, IL-5, and granulocyte macrophage–CSF 
(GM-CSF) (1, 8). Among these, the Th2-associated cytokine IL-5 is 
the most specific cytokine for the eosinophil lineage and is respon-
sible not only for expansion of eosinophils from committed BM 
progenitors, but also for their release into the blood and their sur-
vival following migration into the tissues (1, 8, 9). Once at the site 
of injury, eosinophils can release their cytotoxic granule proteins 
as well as preformed cytokines and lipid mediators, contributing 
in certain circumstances to parasite destruction, but also to exac-
erbation of inflammation and tissue damage, which is particularly 
deleterious when Th2 responses are directed against allergens (1, 
8, 10). It is interesting to note that the role of eosinophils is not 
limited to the effector phase of Th2 responses but also seems to be 
important for the induction of adaptive immunity. Indeed, there 
is evidence of antigen presentation by eosinophils in some exper-
imental models of Th2 responses against helminths or allergens 
(11–13), and recent studies have further shown that eosinophils can 
also promote Th2 immunity through EPO-mediated induction of 
DC activation and migration (14, 15).
Accumulating evidence indicates that, besides their roles in 
Th2 responses, eosinophils also regulate homeostatic process-
es at steady state, thereby challenging the exclusive paradigm of 
the eosinophil as a destructive and inflammatory cell (1, 2, 8, 16). 
Increases in eosinophil numbers are associated with infection and allergic diseases, including asthma, but there is also 
evidence that eosinophils contribute to homeostatic immune processes. In mice, the normal lung contains resident 
eosinophils (rEos), but their function has not been characterized. Here, we have reported that steady-state pulmonary 
rEos are IL-5–independent parenchymal Siglec-FintCD62L+CD101lo cells with a ring-shaped nucleus. During house dust 
mite–induced airway allergy, rEos features remained unchanged, and rEos were accompanied by recruited inflammatory 
eosinophils (iEos), which were defined as IL-5–dependent peribronchial Siglec-FhiCD62L–CD101hi cells with a segmented 
nucleus. Gene expression analyses revealed a more regulatory profile for rEos than for iEos, and correspondingly, mice 
lacking lung rEos showed an increase in Th2 cell responses to inhaled allergens. Such elevation of Th2 responses was linked 
to the ability of rEos, but not iEos, to inhibit the maturation, and therefore the pro-Th2 function, of allergen-loaded DCs. 
Finally, we determined that the parenchymal rEos found in nonasthmatic human lungs (Siglec-8+CD62L+IL-3Rlo cells) were 
phenotypically distinct from the iEos isolated from the sputa of eosinophilic asthmatic patients (Siglec-8+CD62LloIL-3Rhi 
cells), suggesting that our findings in mice are relevant to humans. In conclusion, our data define lung rEos as a distinct 
eosinophil subset with key homeostatic functions.
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plemental Figure 2), suggesting that they were undergoing piece-
meal degranulation, a process during which granule proteins are 
released gradually (34, 35). Some low-density granules displayed 
a central structure that most likely corresponded to the central 
MBP-containing core typical of eosinophil granules (34, 35), and 
contained intragranular vesiculotubular structures previously 
delineated within human eosinophilic granules (35) (Supplemen-
tal Figure 2, arrows and arrowheads, respectively).
In an attempt to determine whether rEos had phagocytic 
properties, naive mice were instilled intratracheally (i.t.) with 
fluorescent beads, and fluorescence was assessed 6 hours lat-
er in lung rEos, AMs, and T lymphocytes (used as positive and 
negative controls, respectively) by flow cytometry and confocal 
microscopy (Supplemental Figure 3A). rEos were able to uptake 
beads, as an average of 8.7% ± 2.3% (mean ± SEM) of these rEos 
showed fluorescence, which was associated with the physical 
presence of beads in their cytoplasm (Figure 1E and Supplemen-
tal Figure 3). Such experiment also supported the fact that rEos 
were truly located within the lung tissue and were not associated 
with the lung vessels. Indeed, beads administered locally via the 
airways were taken up by lung rEos but not by blood monocytes 
or blood eosinophils (Supplemental Figure 3B). Assessment 
of the localization of more than 100 lung eosinophils on Con-
go red– and MBP-stained lung tissue sections from naive mice 
further confirmed that the vast majority of the eosinophils were 
parenchymal (Figure 1, F and G), with less than 10% of eosino-
phils found in the vicinity of bronchi or inside the blood vessels.
rEos were not present at birth but rapidly accumulated in the 
lung until day 7, and the numbers of rEos per milligram of lung tis-
sue did not change significantly from days 7 to 42 after birth (Fig-
ure 1H). In adult mice, rEos were found in comparable numbers in 
the lungs of male and female mice (Figure 1I) and were complete-
ly absent from the broncho-alveolar lavage fluid (BALF) (data not 
shown). In mice from the BALB/c background, lung rEos were 
also found to be parenchymal Siglec-FintCD125intF4/80+CCR3+ 
cells with a ring-shaped nucleus (Supplemental Figure 4).
Lung rEos are not affected by allergic inflammation and dif-
fer from iEos. In the lung, eosinophils are well described in the 
context of allergic asthma, where they can release granule-asso-
ciated cytotoxic molecules and contribute to the inflammatory 
response (36, 37). In order to determine how rEos are influenced 
by allergic inflammation, we assessed the numbers, phenotype, 
and localization of rEos in the lungs of allergic C57BL/6 mice 
during the effector phase of HDM-induced airway allergy (38) 
(Figure 2A). Figure 2B shows that the population of lung rEos 
observed in saline-injected control mice (rEos at steady state, 
referred to hereafter as rEosss) was present in similar numbers in 
HDM-treated mice (rEos in inflammatory conditions, referred 
to hereafter as rEosi). Moreover, rEosi had a similar ring-shaped 
nucleus and expressed the same levels of Siglec-F, CD125, 
F4/80, and CCR3 as did rEosss (blue color, Figure 2, C–E). In 
addition, we found that the numbers of parenchymal eosinophils 
remained unchanged after the onset of airway allergy (Figure 2, 
G–I), supporting the idea that these cells probably corresponded 
to the rEosi detected by flow cytometry (Figure 2, B and C).
As expected in this model of HDM-induced asthma, a pop-
ulation of iEos was recruited into the lungs. iEos showed higher 
In fact, under baseline conditions, eosinophils rapidly leave the 
bloodstream to enter tissues, mainly the gastrointestinal tract, 
adipose tissue, thymus, uterus, and mammary glands, where they 
regulate a variety of important biological functions (1, 2, 8, 16). 
The vast majority of these tissue-resident eosinophils (rEos) are 
found in the nonesophageal portions of the gastrointestinal tract, 
where they promote IgA class switching and the maintenance of 
IgA-expressing plasma cells (17, 18). They also support the devel-
opment of Peyer’s patches and mucus production in the small 
intestine (18). rEos present in the adipose tissue produce IL-4, 
thereby favoring the polarization of adipose macrophages toward 
the alternatively activated phenotype (19). Alternatively activated 
macrophages play a crucial role in glucose homeostasis and devel-
opment of beige fat (19, 20), which is known to protect against 
obesity (21). In the thymus, rEos have the capacity to promote thy-
mocyte apoptosis and are therefore thought to contribute to the 
process of negative T cell selection (22). Finally, a role for rEos in 
preparing the uterus for pregnancy and in regulating mammary 
gland development has been proposed (23, 24).
While rEos have also been identified in the mouse lung (25–27), 
they have not been fully characterized, and their role remains to be 
determined. Here, we show that mouse lung rEos display unique 
morphological and phenotypical features that unambiguously 
distinguish them from the inflammatory eosinophils (iEos) that 
are recruited to the lung during house dust mite (HDM)–induced 
allergic airway inflammation. Moreover, we demonstrate that lung 
rEos are endowed with the striking capacity to prevent the develop-
ment of pulmonary Th2 immunity against inhaled allergens, there-
by contributing to the maintenance of lung homeostasis in mice. 
Finally, by comparing lung rEos and iEos in humans, we provide 
evidence that our findings in mice are relevant to humans.
Results
Lung rEos are parenchymal Siglec-FintCD125int cells with a ring-shaped 
nucleus. First, we aimed to better characterize lung rEos of naive 
mice. In order to avoid any contamination by blood cells, whole 
lungs of adult C57BL/6 mice were first extensively flushed with 
PBS through the right ventricle and were then digested to obtain 
a single-cell suspension. Using a flow cytometry–based approach, 
lung eosinophils were delineated, among living singlet CD45.2+ 
cells (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI85664DS1), with a com-
bination of Abs recognizing Siglec-F and the subunit α of the 
IL-5 receptor (IL-5Rα or CD125) (28–31). This approach identi-
fied 3 cell populations, namely intermediate Siglec-F (Siglec-Fint) 
CD125int , Siglec-FhiCD125int, and Siglec-FdimCD125hi cells (Figure 
1A). The Siglec-FintCD125int cell population exhibited features of 
eosinophils, i.e., an eosinophilic cytoplasm (Figure 1B), expression 
of F4/80 (32), and expression of the eosinophil eotaxin recep-
tor (CCR3) (33) (Figure 1C). Notably, Siglec-FintCD125int eosin-
ophils consistently exhibited a ring-shaped nucleus (Figure 1B). 
Siglec-FhiCD125int and Siglec-FdimCD125hi cells were identified as 
F4/80hiCCR3– alveolar macrophages (AMs) and F4/80–CCR3– 
neutrophils, respectively (Figure 1, B and C). Ultrastructural anal-
ysis of FACS-sorted Siglec-FintCD125int rEos revealed secondary 
granules with variable levels of density (Figure 1D, high [arrows], 
intermediate [asterisks], and low [arrowheads] density, and Sup-
Downloaded from http://www.jci.org on August 31, 2016.   http://dx.doi.org/10.1172/JCI85664
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3jci.org
Figure 1. Characterization of lung rEos in naive C57BL/6 mice. (A) Dot plot of lung leukocytes 
according to Siglec-F and CD125 expression. Numbers indicate the percentage of gated cells. 
Neutros, neutrophils. (B) Photographs of the FACS-sorted cell populations gated in A. (C) His-
tograms of F4/80 and CCR3 expression in the cell populations shown in B. (D) Representative 
electron microscopy photographs of rEos (left panel, representative of more than 100 individ-
ual cells analyzed) and rEos-associated granules (right panels). Arrows, asterisks, and arrow-
heads indicate secondary granules with high, intermediate, and low densities, respectively. (E) 
Phagocytic potential of rEos 6 hours after local i.t. instillation of fluorescent beads. Number 
indicates the percentage of bead-positive cells. (F) Congo red– and (G) MBP-stained lung 
sections. Arrows indicate Congo red– and MBP-positive eosinophils, respectively. (H) Kinetics 
of appearance of lung rEos after birth. (I) Absolute numbers of rEos in the lungs of female and 
male mice. (H and I) Results represent the mean ± SEM as well as individual values. *P < 0.05, 
**P < 0.01, and ***P < 0.001, by 1-way ANOVA, followed by Tukey’s test for multiple compari-
sons on log-transformed values (H) or by 2-tailed Student’s t test on square root–transformed 
values (I). Data in A–G are representative of 1 of more than 8 mice, each giving similar results. 
Data in H and I were pooled from 2 and 3 independent experiments, respectively (n = 4–6/
group and 14/group, respectively). Scale bars: 1 μm (D) and 10 μm (B, E–G). Max, maximum.
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levels, but not on the surface of iEos (Figure 4, A–C). Conversely, 
rEosss and rEosi expressed low levels of CD101, whereas CD101 
was highly expressed on the surface of iEos (Figure 4, A–C). Nota-
bly, CD101 could be used to distinguish between rEosi (CD101lo) 
and iEos (CD101hi) when gating on the total population of eosino-
phils in the lungs of HDM-challenged mice (Figure 4D). Interest-
ingly, the expression levels of CD62L and CD101 on rEosss were 
similar to those seen on rEosi from HDM-treated allergic mice 
(Figure 4, A and B), concordant with our microarray data (Figure 
3B) and with the hypothesis that rEos, like iEos, are differentiat-
ed cells released from the BM that are not able to modify their 
phenotype over the course of allergic tissue inflammation. If this 
were true, the 2 Siglec-FintCD62L+CD101lo (i.e., rEosi) and Siglec-
FhiCD62L–CD101hi (i.e., iEos) eosinophil populations present in 
the lungs should also be detected in the blood. We verified this 
assumption and found that only Siglec-FintCD62LhiCD101– rEos-
like cells were present in the blood of naive mice (Figure 5A). How-
ever, 2 phenotypically distinct populations of rEos- and iEos-like 
(Siglec-FhiCD62LloCD101+) cells were indeed found in the blood of 
HDM-treated allergic mice (Figure 5B), suggesting that both lung 
rEos and iEos are terminally differentiated cells.
Given that small intestinal eosinophils (Int Eos) have previously 
been shown to be phenotypically different from lung rEos (26), we 
extended this analysis by comparing their expression of CD62L and 
CD101. Int Eos were found to be Siglec-FintCD125intCD101– cells 
expressing F4/80 and CCR3 and exhibited a ring-shaped nucleus. 
However, as compared with lung rEos, which expressed CD62L, Int 
Eos were found to be negative for CD62L (Supplemental Figure 8).
rEos are independent of IL-5 for their presence in the lung. IL-5 
is important for the expansion of eosinophils in the BM, eosino-
phil release, and survival in the blood in response to different 
inflammatory stimuli (1, 8, 9, 51). Yet, basal blood eosinophil 
numbers remain unchanged in Il5–/– mice (52), and, as shown in 
Figure 2B, the numbers of lung rEos remained unaffected by the 
presence of allergic inflammation, at a time point when IL-5 lev-
els were significantly increased in the lungs (Supplemental Figure 
9, A and B). Hence, we next wondered to what extent rEos and 
iEos were dependent on IL-5 for their presence in the blood and 
for their recruitment to the lung tissue. First, we treated naive 
C57BL/6 mice i.p. with 100 μg neutralizing Abs directed against 
IL-5 (α–IL-5) and quantified the numbers of rEos in the lungs 24 
hours later (Figure 6A, left panel). α–IL-5 treatment did not signifi-
cantly affect the numbers of rEosss in the lungs of naive animals 
(Figure 6B, left panel) or the numbers of rEos-like blood eosino-
phils (Figure 6C, left panel). In addition, the numbers of lung rEos 
remained unchanged in naive mice treated 3 times daily with 100 
μg α–IL-5, which corresponds to the time during which 90% of 
lung rEos are replaced (26) (Figure 6D). Second, HDM-sensitized 
and challenged C57BL/6 mice were treated i.p. with 100 μg α–IL-5 
one hour before the last intranasal (i.n.) HDM challenge (Figure 
6A, right panel), and the numbers of rEosi and iEos were evalu-
ated 3 days later. Interestingly, α–IL-5 treatment did not impact 
the numbers of rEosi but substantially inhibited the recruitment of 
iEos in the lungs of α–IL-5–treated mice compared with that seen 
in isotype-injected mice (Figure 6B, right panel). Similarly, rEos-
like blood eosinophil levels seemed not to be affected by α–IL-5 
treatment, while iEos-like blood eosinophil levels were signifi-
levels of Siglec-F expression (red color, Figure 2C), a high-
ly segmented nucleus (Figure 2D), and were also positive for 
F4/80 and CCR3 (Figure 2E). Electron microscopic analysis of 
FACS-sorted iEos revealed dense secondary granules, without 
apparent signs of degranulation (Figure 2F, arrows; representa-
tive of >100 cells analyzed) and a segmented nucleus (Figure 
2F). HDM-induced iEos, unlike rEos, were mainly localized in 
the peribronchial area (Figure 2, G–I) and were recruited in the 
BALF (Figure 2, J and K). Similar results were found in BALB/c 
mice (Supplemental Figure 5).
Lung rEos and iEos have distinct gene expression profiles. So far, 
our data suggest that rEos are not influenced by the HDM-induced 
allergic environment and are distinct from iEos. To further con-
firm these observations, we isolated steady-state rEos from naive 
mice (rEosss), rEos from HDM-treated mice (rEosi), and iEos from 
HDM-treated mice (iEos) (Supplemental Figure 6) and compared 
their transcriptome by microarrays. Hierarchical clustering based 
on all expressed genes showed that rEosss clustered together with 
rEosi (Supplemental Figure 7A). Conversely, the transcriptom-
ic signature of iEos was distant from that of rEos, regardless of 
whether they originated from naive or HDM-treated allergic mice. 
Indeed, the coefficients of correlation were very low between iEos 
and rEos (r < 0.25, Supplemental Figure 7A). Volcano plot repre-
sentation of the differentially expressed genes between rEosss 
and rEosi showed that, using a biological fold change (FC) of 2 
and a P value of less than 0.01, not a single gene was differential-
ly expressed between rEosss and rEosi (Figure 3A). Increasing the 
threshold to a P value of less than 0.05 only revealed 3 differen-
tially expressed genes between these 2 cell populations (data not 
shown), strongly suggesting that rEos are not impacted by the 
HDM-induced proallergic environment. However, using the same 
thresholds (FC >2; P <0.01), more than 160 genes were differen-
tially expressed between iEos and rEosss and between iEos and 
rEosi (Figure 3A and Supplemental Figure 7B), reinforcing the idea 
that iEos and rEos represent distinct cell populations.
On the basis of a thorough bibliographical search, we selected 
the differentially expressed genes known to be associated with the 
modulation of inflammatory and immune responses, which led to 
28 genes whose expression was upregulated in iEos and 20 genes 
whose expression was upregulated in rEos (Figure 3B). iEos had 
high expression of several proinflammatory genes such as Slc3a2 
(39), Tlr4 (40), C3ar1 (41, 42), Il13ra1 (43), and Il6 (44), consis-
tent with the known function of iEos as proinflammatory effector 
cells (Figure 3B). In contrast, rEos expressed several genes such 
as Anxa1 (45, 46), Nedd4 (47), Runx3 (48), Serpinb1a (49), and Ldlr 
(50) that are implicated in the negative regulation of immune 
responses and tissue homeostasis (Figure 3B). These analyses sug-
gested that, in addition to their unique localization and morpholo-
gy, rEos and iEos were also functionally different.
Expression of CD62L and CD101 discriminates between mouse 
lung rEos and iEos. Given the list of differentially expressed genes 
shown in Figure 3B, we sought to find surface markers allow-
ing a better discrimination between rEos and iEos. Expression 
of several surface molecules was assessed by flow cytometry on 
rEosss, rEosi, and iEos. We found that L-selectin, also known as 
CD62L (encoded by Sell in mice, see Figure 3B), was specifical-
ly expressed on the surface of rEosss and rEosi, albeit at variable 
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and iEos from HDM-treated allergic mice (Figure 6E). AMs were 
chosen as negative controls. In addition, rIL-5 significantly pro-
moted survival of the 3 FACS-sorted eosinophil subpopulations, 
with an effect that was significantly more pronounced for rEos 
than for iEos 24 hours after treatment (Figure 6F). Altogether, our 
data obtained from in vivo experiments indicate that the presence 
of lung rEos and blood rEos-like eosinophils are independent of 
IL-5, even though rEos can respond to rIL-5 in vitro.
rEos, but not iEos, can inhibit the development of Th2 responses 
to HDM and the pro-Th2 potential of DCs. Our microarray data sug-
gested that lung rEos could play immunoregulatory roles (Figure 
3B). This is consistent with recent studies showing homeostat-
ic functions for eosinophils in several organs (8, 16, 53). These 
cantly decreased (Figure 6C, right panel). In addition, injection 
of recombinant IL-5 (rIL-5) into naive mice did not promote the 
recruitment of rEos-like cells or rEos in the blood and the lungs, 
respectively (Supplemental Figure 9, C and D). These results sup-
port the idea that rEos, as opposed to iEos, do not depend on IL-5 
for their presence in the blood or recruitment to the lungs.
Nevertheless, the fact that rEos and iEos expressed similar 
levels of IL-5Rα (CD125) (see Figure 2C) suggested that rEos, like 
iEos, could respond to IL-5. To test this hypothesis, we assessed 
the activation of ERK1/2 and the survival of primary lung rEos and 
iEos stimulated in vitro with or without rIL-5. We found that rIL-5 
treatment induced a significant increase in the levels of phosphor-
ylated ERK (p-ERK) in rEosss from naive mice, as well as in rEosi 
Figure 2. Characterization of lung rEos and iEos in HDM-challenged C57BL/6 mice. (A) Experi-
mental outline. i.n., intranasal. (B) Absolute numbers of lung eosinophil subsets. (C) Dot plot of 
lung leukocytes according to Siglec-F and CD125 expression. Numbers indicate the percentage of 
gated cells. (D) Photographs of the 2 lung eosinophil subsets. (E) Histograms of F4/80 and CCR3 
expression in the cell populations shown in D. (F) Representative electron microscopy photograph 
of iEos (>100 individual cells analyzed). Arrows indicate secondary granules. (G) Congo red– and (H) 
MBP-stained lung sections. Arrows indicate Congo red– and MBP-positive eosinophils, respectively. 
(I) Quantification of parenchymal and peribronchial eosinophils in Congo red–stained lung sections. 
Eos, eosinophils. (J) Dot plot of BALF leukocytes according to Siglec-F and CD125 expression. 
Numbers indicate the percentage of gated cells. (K) Photographs of the gated cell populations 
in J. (B and I) Results represent the mean ± SEM as well as individual values (n = 5–6/group) and 
are representative of 1 of more than 4 independent experiments. **P < 0.01 and ***P < 0.001, by 
(B) a mixed-effects model, followed by Tukey’s test for multiple comparisons on log-transformed 
values, and (I) a Mann-Whitney U test. (C–H) Data are representative of 1 of more than 8 mice, each 
of them giving similar results. Scale bars: 10 μm (D, G, and H) and 1 μm (F). Neutros, neutrophils.
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homeostatic effects have been demon-
strated experimentally by the use of 
transgenic mice such as ΔdblGATA 
mice, in which a targeted deletion of 
the double palindromic GATA-1–bind-
ing site in the Gata1 promoter results in 
eosinophil deficiency (54). Given that 
ΔdblGATA mice lacked lung rEos (Sup-
plemental Figure 10A) and that only 
rEos, but not iEos, are present in the 
lungs under normal conditions, Δdbl-
GATA mice were chosen as a pertinent 
tool for studying rEos function.
In the gut, eosinophils have been 
shown to be required for gut homeosta-
sis through the generation and mainte-
nance of IgA+ plasma cells (17). How-
ever, the situation was different in the 
lungs, as the numbers of IgA+ plasma 
cells were not reduced in the lungs of 
ΔdblGATA mice compared with num-
bers detected in the lungs of control 
mice (Supplemental Figure 10B).
A unique feature of the lung muco-
sa resides in its continuous exposure to 
allergens and immunostimulatory mole-
cules present in the ambient air, and the 
lung innate immune system has devel-
oped strategies to ignore or tolerate these 
foreign antigens and prevent the devel-
opment of aberrant Th2 responses that 
are classically associated with asthma 
(55–58). As rEos express genes, namely, 
Anxa1 (46), Runx3 (48), and Ldlr (50), 
involved in the prevention of Th2 and 
asthmatic responses (Figure 3B), we pos-
tulated that they could contribute to lung 
homeostasis by inhibiting airway sensiti-
zation to allergens. To test this hypothe-
sis, rEos-deficient ΔdblGATA and control 
mice received an i.n. instillation of a low 
dose (5 μg) of a clinically relevant mixture 
of HDM. Five days after HDM injection, 
Figure 3. Transcriptomic profile of rEosss, 
rEosi, and iEos. (A) Summary of differentially 
expressed genes (P < 0.01; FC >2) in each 
pairwise comparison showing differentially 
expressed genes in red and blue in a volcano 
plot, the total number of differentially 
expressed genes in the middle of the bidirec-
tional arrows, and arrowheads showing the 
direction of differential expression for all and 
highly (FC 4–16) differentially expressed genes. 
(B) Heatmap showing the relative expression 
of differentially expressed genes associated 
with the regulation of inflammatory and 
immune responses between iEos and rEos.
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mediastinal lymph node (MLN) cell proliferation and cytokine pro-
duction following in vitro restimulation with HDM were assessed 
(Figure 7A). Interestingly, MLN cells from HDM-treated ΔdblGA-
TA mice proliferated significantly more and produced more of the 
Th2-associated cytokines IL-4, IL-5, and IL-13 as compared with 
MLN cells from HDM-treated control mice (Figure 7, B and C). Since 
5 μg i.n. HDM exposure also promoted a weak innate recruitment of 
iEos (i.e., Siglec-FhiCD101hi cells) in the lung (albeit 300 times less 
significant than the recruitment observed in HDM-allergic mice, 
Supplemental Figure 11), we assessed the potential contribution of 
such iEos in Th2 sensitization by treating WT mice i.p. with α–IL-5 
Abs (i.e., a regimen that has been shown to inhibit the recruitment 
of iEos into the lungs without affecting rEos numbers [see Figure 
6B and Supplemental Figure 11]) 1 hour before sensitization. As 
shown in Figure 7, B and C, α–IL-5–treated iEos-depleted WT 
mice were not more susceptible to HDM-induced Th2 responses 
than were isotype-treated control mice. These results demon-
strated that rEos, but not iEos, mediate the increased susceptibil-
ity to HDM observed in ΔdblGATA mice. Intranasal sensitization 
with a high dose of HDM, which likely bypass innate immune 
regulatory mechanisms in the lung, induced similar MLN cell 
responses between ΔdblGATA and control mice (Supplemental 
Figure 12), in agreement with previous findings (59, 60). These 
results show that a lack of rEos is associated with increased Th2 
sensitization to low doses of allergens and support the idea that 
rEos can exert homeostatic functions, either by inhibiting T cells 
directly or by impairing the ability of antigen-presenting cells to 
induce Th2 responses. We assessed the effects of rEos on T cells 
and showed that, when cocultured with activated T cells in vitro, 
rEos did not impact the ability of T cells to secrete Th2 cytokines 
(Supplemental Figure 13A), suggesting that they do not act on 
T cells directly. We also found that, unlike conventional DCs, 
rEos were not able to migrate to the MLNs following treatment 
with 5 μg HDM (Supplemental Figure 13, B and C). Since rEos 
are located in the lung parenchyma (Figure 1, F and G), i.e., in the 
vicinity of DCs (55), we postulated that they may contribute to 
lung homeostasis by inhibiting DC function locally, as reported 
previously by our group for lung interstitial macrophages (IMs) 
(55). rEos, unlike IMs, were not able to secrete IL-10 upon LPS 
stimulation (Supplemental Figure 13D), but were able to inhibit 
the maturation of antigen-pulsed in vitro–cultured BM-derived 
DCs (BMDCs). Indeed, when BMDCs were cocultured with 
FACS-sorted rEos and pulsed with OVA (i.e., grade V OVA con-
taminated with a low dose of LPS [OVALPS]), OVALPS-BMDCs cocul-
tured with rEos exhibited significantly decreased surface expression 
of the costimulatory molecules CD80 and CD86 as compared with 
OVALPS-BMDCs alone (Figure 7D), confirming that rEos can inhibit 
DC maturation. Conversely, neither FACS-sorted lung iEos nor Int 
Eos were able to inhibit the maturation of cocultured DCs (Figure 
7D and Supplemental Figure 14, respectively). To test whether rEos 
can also affect DC proallergic functions, OVALPS-pulsed BMDCs 
cocultured with or without rEos were then injected i.t. into naive 
recipient mice. OVALPS-BMDCs cocultured with AMs (i.e., a negative 
control) (55), IMs (i.e., a positive control) (55), or iEos were also ana-
Figure 4. Identification of discriminating surface markers for mouse 
lung rEos and iEos. (A and B) Representative flow cytometric histo-
grams of CD62L and CD101 expression on (A) rEosss from naive C57BL/6 
mice and (B) rEosi and iEos from HDM-treated allergic C57BL/6 mice. 
(C) Quantification of CD62L and CD101 expression levels on the surface 
of rEosss, rEosi, and iEos, expressed as the fold change (FC) increase 
in mean fluorescence intensity (MFI) as compared with the control 
MFI. Data represent the mean ± SEM as well as individual values and 
are pooled from 3 to 5 independent experiments (n = 7–13/group). 
(D) Histograms of CD62L and CD101 expression on rEosi (blue) and 
iEos (red) and total lung eosinophils (Siglec-Fint/hiCD125int, black) from 
HDM-treated allergic C57BL/6 mice. (C) *P < 0.05, **P < 0.01, and 
***P < 0.001, by 1-way ANOVA, followed by Tukey’s test for multiple 
comparisons. FMO, fluorescence minus 1.
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Lung parenchymal eosinophils exist in humans and are pheno-
typically distinct from iEos found in asthmatic airways. To assess 
the human relevance of our findings, we examined Congo red– 
and MBP-stained lung sections from 5 healthy human donors 
and 5 asthmatic patients (Figure 8A and Supplemental Table 
1) and quantified the numbers of eosinophils found in the lung 
parenchyma and peribronchial area (Figure 8B). As in mice, we 
detected eosinophils in similar numbers in the lung parenchyma 
of healthy donors and asthmatic subjects (Figure 8, A and B and 
Supplemental Figure 16A), supporting the existence in humans 
of lung parenchymal rEos whose numbers seemed unaffected 
by lung inflammation. Additional eosinophils were also found in 
the peribronchial area of asthmatic lungs, probably representing 
classical iEos infiltrating the bronchi (Figure 8, A and B). Of note, 
by assessing the average numbers of rEos per microscopic field in 
mouse and human lung sections (see Figure 2I [mouse] vs. Figure 
8B [human]), our data support the idea that the density of the rEos 
population is comparable in mouse and human lungs.
To further investigate the potential existence of distinct eosin-
ophil subsets in humans, we assessed the surface expression of 
Siglec-8, CD62L, and CD101 (i.e., the human orthologs of the dis-
criminating surface markers found in the mouse) on 2 populations 
lyzed. Ten days after adoptive transfer, mice were challenged with 
OVA aerosols to induce airway allergic inflammation (Figure 7E). As 
expected, mice that received OVALPS-BMDCs or OVALPS-BMDCs/
AMs, but not those injected with PBS-BMDCs, developed eosino-
philia in the BALF, but such eosinophilia was markedly attenuated 
in mice that received OVALPS-BMDCs cocultured with rEos, but not 
those cocultured with iEos (Figure 7F). In addition, T cell prolifer-
ation and Th2 cytokine production of bronchial lymph node (LN) 
cells restimulated in vitro with OVA were substantially decreased 
in mice sensitized with OVALPS-BMDCs cocultured with rEos com-
pared with those sensitized with OVALPS-BMDCs alone or cocul-
tured with AMs or iEos and reached levels similar to those measured 
in mice sensitized with unpulsed BMDCs (Figure 7, G and H). Simi-
lar immunosuppressive effects on DC maturation and function were 
observed with blood rEos-like cells cocultured with OVALPS-BMDCs 
(Supplemental Figure 15).
Together, these results show that a) at the time of exposure to a 
low dose of HDM, the absence of rEos, but not the absence of iEos, 
results in increased Th2 sensitization to HDM, and that 2) rEos, 
as opposed to iEos, are able to inhibit the proallergic functions of 
DCs in vitro, thereby preventing the development of DC-induced 
airway allergy.
Figure 5. Identification of rEos-like and iEos-like eosinophils in the blood of naive and HDM-treated C57BL/6 mice. White blood cells from (A) naive and 
(B) HDM-treated allergic C57BL/6 mice were analyzed by flow cytometry (see Figure 2A for experimental outline). Living singlet CD45.2+SSChi cells were 
analyzed according to Siglec-F and CD125 expression, and representative flow cytometric histograms of CD62L and CD101 expression in the gated popula-
tions are shown. Data shown are representative of 1 of more than 8 mice analyzed from 3 independent experiments, each of them giving similar results. 
FMO, fluorescence minus 1; FSC, forward scatter; SSC, side scatter.
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Figure 6. Sensitivity and responsiveness of eosinophil subsets to in vivo α–IL-5 and in vitro rIL-5 treatments. (A) Experimental outline for data 
shown in B–D. (B–D) Effects of in vivo α–IL-5 (TRFK5) treatment on the numbers of (B and D) lung and (C) blood eosinophil subsets in naive and 
HDM-treated allergic C57BL/6 mice. (E) Phosphorylation of ERK1/2 was assessed by phospho-flow cytometry on freshly isolated eosinophils and AMs 
stimulated in vitro with rIL-5 or vehicle. Representative flow cytometric histograms and quantification of p-ERK levels. (F) Survival (as assessed by 
incorporation of 7-AAD) of FACS-sorted lung eosinophil subsets stimulated ex vivo, with or without rIL-5, for the indicated times. More than 90% of the 
cells were negative for 7-AAD before stimulation. (B–F) Data represent the mean ± SEM as well as individual values and are pooled from 2 to 3 indepen-
dent experiments (n = 5–11/group). *P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed Student’s t test (B and C, left panels, and D) or a mixed-effects 
model, followed by Tukey’s test for multiple comparisons (B and C, right panels) on log-transformed values and (E and F) by Welch’s t test (for com-
parison of vehicle vs. IL-5–treated groups) or 1-way ANOVA, followed by Tukey’s test for multiple comparisons (for comparison of IL-5–treated subsets). 
cpm, counts per minute.
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Figure 7. Assessment of rEos immunosuppressive functions using eosinophil-deficient ΔdblGATA mice and DC coculture experiments. (A) Experi-
mental outline for B and C. Briefly, the indicated groups of mice were sensitized i.n. with 5 μg HDM or injected with saline, and the MLN cell response 
to HDM was assessed 5 day later. Some WT mice also received an i.p. injection of α–IL-5 or isotype Abs 1 hour before HDM instillation. (B) Proliferation 
of MLN cells restimulated for 3 days with or without HDM. (C) Cytokine concentrations in culture supernatants of MLN cell cultures restimulated with 
HDM. (D) Expression of the indicated maturation markers on the surface of OVALPS-pulsed BMDCs cultured alone or cocultured with rEos or iEos for 12 
hours. (E) Experimental outline for F–H. (F) Total and eosinophil cell counts in the BALF. (G) Proliferation of LN cells restimulated for 3 days with or 
without OVA. (H) Cytokine concentrations in culture supernatants of LN cell cultures restimulated with OVA. Data shown represent the mean ± SEM 
and were (B and C) pooled from 3 independent experiments (n = 6 biological replicates/group) and (D–H) are representative of 1 of 4 different batches 
of BMDCs cocultured with primary rEos, AMs, or IMs and 1 of 3 different batches of BMDCs cocultured with primary rEos or iEos isolated from indepen-
dent cohorts of mice. *P < 0.05, **P  < 0.01, and ***P < 0.001, by 2-way ANOVA (B, F, and G) or 1-way ANOVA (C, D, and H), followed by Tukey’s test for 
multiple comparisons. Iso, isotype Abs; Sal, saline.
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sue localization of lung rEos was also evidenced by the fact that the 
number of rEos in the lung exceeded 4 × 105, which corresponds 
to 2 times the number of eosinophils present in the entire blood 
circulation of C57BL/6 mice (69, 70). Finally, time-course studies 
showed that rEos were not present in the lung at birth but gradually 
increased in number to reach a maximal density by day 7. This is 
in agreement with a previous report showing that murine thymic 
rEos reach a plateau by 2 weeks of age (22). These data tend to link 
the colonization of the lung by rEos with the development of the 
microbiota, but this needs further investigation.
Over the past few decades, most of the immune cell popula-
tions have been divided into different subpopulations with specific 
phenotypes and functions. However, it is still believed that inflam-
matory and homeostatic eosinophils are the same cells in differ-
ent activation states. Although it cannot be ruled out that rEos may 
transform into iEos, our work provides evidence that lung rEos and 
iEos represent distinct terminally differentiated eosinophil sub-
sets. First, the phenotypic features of rEos remained unchanged 
and differed from those of iEos during allergic airway inflamma-
tion. Siglec-FintCD125intCD62L+CD101lo rEos cohabited with iEos, 
which were defined as Siglec-FhiCD125intCD62L–CD101hi cells 
with a segmented nucleus. Microarray analyses further revealed 
that rEos and iEos had substantially different gene expression 
signatures, but that not a single gene was differentially expressed 
at a significant level (P < 0.01, FC >2) between rEosss and rEosi. 
Second, rEos and iEos were confined to different compartments 
of the lung. iEos were localized in the peribronchial areas, whereas 
rEos resided in the parenchyma, even during allergic inflamma-
tion. As the inflammation is thought to be mainly restricted to the 
peribronchial connective tissue in asthma (68), this observation 
could account for the fact that rEos were not at all affected by 
the inflammatory process. Third, we did not find any continuity 
between the rEos and iEos subsets. As rEos displayed an immature 
phenotype, attested by their ring-shaped nucleus, it is tempting to 
speculate that these cells are precursors of iEos. However, if this 
were true, cells having an intermediate state between rEosss and 
iEos should have been detected in HDM-challenged asthmatic 
mice. For example, rEosi should have displayed an intermediate 
gene expression profile or an intermediate morphology compared 
with rEosss and iEos, which was not the case. The only apparent 
continuity between rEos and iEos was that Siglec-F expression 
was only slightly increased on iEos compared with that observed 
on rEos, supporting the idea put forth by Abdala Valencia and 
colleagues (25), in which rEos can increase their expression of 
Siglec-F to become iEos during the inflammatory process. How-
ever, when analyzed for their expression of CD101, one of the 
most discriminating markers identified by microarrays, the rEosi 
and iEos subpopulations did not overlap at all. Finally, rEos- and 
iEos-like eosinophils were found in the blood, suggesting that 
the differentiation of both cell subsets mainly occurs before their 
recruitment to the lungs.
Mice lacking functional GATA1 were devoid of lung rEos, 
demonstrating that these cells develop in the BM from eosin-
ophil progenitors. Here, we provided evidence that rEos and 
rEos-like cells are not dependent on IL-5 for their presence in the 
lungs and the blood, respectively. Nevertheless, we also showed 
that rEos express the receptor for IL-5 and can respond to IL-5 in 
of human primary eosinophils (Figure 8C and Supplemental Fig-
ure 16B): a) eosinophils freshly isolated from normal lung tissue 
(rEos) (Supplemental Table 2), with more than 90% of eosinophils 
residing in the parenchyma (see also Supplemental Methods) and 
b) iEos found in the sputa of asthmatic subjects (Supplemental 
Table 3) (Figure 8C). rEos and iEos could not be distinguished 
from each other on the basis of morphology (Figure 8C) or on the 
basis of surface levels of Siglec-8 and CD101 (Figure 8, D and E). 
However, interestingly, iEos were consistently found to be nega-
tive for CD62L expression, whereas rEos were expressing variable 
levels of CD62L, reminiscent of what we observed in mice (Figure 
8, D and E). In search for a marker that, like CD101 in mice, was 
upregulated in iEos, but not rEos, we assessed the surface expres-
sion of several markers whose mRNA levels have been shown to 
be upregulated in blood eosinophils from asthmatic subjects as 
compared with those from healthy controls (61). Among the can-
didates tested, we found that expression of IL-3R was significantly 
higher in iEos compared with that detected in rEos (Figure 8, D 
and E). While based on a limited number of samples analyzed, 
our data support the existence of positionally and phenotypically 
distinct subsets of lung eosinophils in humans and identify IL-3R 
and, to a lesser extent, CD62L as 2 promising markers allowing 
discrimination between such lung rEos and iEos.
Discussion
Lung rEos constitute one abundant but little-characterized popu-
lation of tissue eosinophils (26). Here, we showed that pulmonary 
rEos express intermediate levels of Siglec-F and CD125, two non-
specific markers of eosinophils (30, 31). Siglec-F was also found 
to be expressed by AMs, a finding consistent with that of previous 
studies (28, 29), and by lung neutrophils, which has not been report-
ed before. Although CD125 expression is thought to be restricted to 
eosinophils and B-1 cells in mice (28, 29, 62–64), we unexpectedly 
found that lung neutrophils expressed high levels of CD125, suggest-
ing that these cells may also be influenced by IL-5. Supporting this 
finding, mouse neutrophils have been shown to migrate in response 
to rIL-5 treatment (65). These findings are particularly important 
in light of the numerous mouse studies, in which eosinophils were 
identified on the basis of their high granularity and expression of 
Siglec-F and/or CD125 and in which a possible contamination with 
neutrophils may have led to misinterpretations.
Microscopy revealed that lung rEos have a ring-shaped nucle-
us, which has been reported recently (25). The presence of such a 
nucleus in mouse eosinophils is considered a sign of cell immatu-
rity (66, 67), suggesting that pulmonary rEos retain an immature 
phenotype when spreading into the lungs. Using histochemistry, 
we further showed that lung rEos were located in the parenchyma, 
which contrasts with the localization of eosinophils in asthma, in 
which eosinophils are classically thought to infiltrate the peribron-
chial area (68). Using electron microscopy, we next showed that 
rEos exhibited signs of piecemeal degranulation, suggesting that 
they are actively secreting their granule contents at steady state. 
Another interesting feature of lung rEos was their ability to phago-
cytose fluorescent beads, suggesting a scavenger function for these 
cells. Given that fluorescent beads were unable to reach the circula-
tion, this experiment also definitively proved that pulmonary rEos 
were located in the tissue rather than in the blood vessels. The tis-
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negative regulation of Th2 cell responses in the lung. Indeed, mice 
deficient for annexin A1, a phospholipase A2 inhibitor encoded by 
the Anxa1 gene, or for RUNX3, the transcription factor encoded by 
the Runx3 gene, spontaneously develop asthma-like diseases (46, 
48). Moreover, mice lacking the low-density lipoprotein receptor, 
the product of Ldlr, are more prone than are WT controls to devel-
oping airway hyperreactivity when sensitized to allergens (50). 
All these observations prompted us to investigate whether lung 
rEos, which overexpressed those genes, were endowed with the 
capacity to prevent airway allergy. Using a model of sensitization 
to a low dose of HDM, we showed that rEos-deficient ΔdblGATA 
mice, as opposed to α–IL-5–treated iEos-depleted WT mice, exhib-
ited increased sensitivity to HDM compared with control mice, 
thereby confirming our hypothesis. This unexpected immunosup-
pressive function of lung rEos strikingly contrasts with the known 
proinflammatory and pro-Th2 roles of pulmonary iEos (1, 8, 12, 13, 
15, 36, 59, 79) and further reinforces the idea that these eosinophil 
subsets are functionally different.
Our results are in apparent contradiction with those of previ-
ous studies that also used eosinophil-deficient mice, suggesting 
that eosinophils are not influencing the sensitization phase of 
OVA- or HDM-induced airway allergy (59, 60). However, in these 
studies, the authors used either a model of systemic sensitization 
with OVA and the pro-Th2 adjuvant alum or models of i.n. sen-
sitization with high doses of HDM (i.e., 2 × 50 μg or 5 × 25 μg). 
At these doses, which are far above the common environmental 
HDM concentrations, sensitization occurred in 100% of the mice. 
Our hypothesis is that supraenvironmental doses of HDM trigger 
potent pro-Th2 mechanisms that bypass the innate immune reg-
ulatory mechanisms of the lung, as it is also the case with alum-
based sensitization. This notion is also supported by our observa-
tion that a single i.n. exposure of mice to 100 μg HDM induced 
similar Th2 cell responses in both ΔdblGATA and control mice.
No eosinophils were found in the MLNs following stimula-
tion with low doses of HDM, demonstrating that, under these 
conditions, rEos are unable to migrate to the draining LNs and 
therefore must act locally to weaken allergic sensitization. This 
is not surprising given that the other innate immune cells known 
to control lung Th2 responses are also located in the parenchy-
ma. Indeed, plasmacytoid DCs, which play a key role in limiting 
allergic sensitization in the airways, are parenchymal cells (80). 
Moreover, lung IMs, which are in close contact with pro-Th2 
DCs in the parenchyma, have the ability to prevent DC-medi-
ated Th2 sensitization in an IL-10–dependent manner (55). We 
showed here that lung rEos were not able to produce IL-10 but, 
like IMs, could impact DC maturation in vitro and the ability of 
vitro. The biological effects of IL-5 on rEos, however, remain to 
be determined. One likely scenario is that lung rEos, as opposed 
to iEos, are not affected by IL-5 during allergen-induced inflam-
mation, because they are not reached by IL-5 as a result of their 
specific parenchymal localization. It is indeed thought that IL-5–
secreting cells such as effector Th2 cells are mainly infiltrating 
the peribronchial area (71, 72), where rEos are absent. Supporting 
this notion, transcriptomic analyses of rEos showed no differen-
tially expressed genes between steady state and the effector phase 
of allergic inflammation, at a time when IL-5 is increased in the 
lung. In this context, if rEos were under the influence of IL-5, 
we would have expected to find differentially expressed genes 
between rEosss and rEosi as a result of IL-5 exposure. Of note, such 
an IL-5 signature was present in iEos, which upregulated several 
IL-5–dependent genes such as Bcl6, Ccnd2, and Sema4a, as com-
pared with rEosi (73). The IL-5–independent rEos numbers are 
also reminiscent of the results from Kopf et al. (52), who reported 
that the basal numbers of blood eosinophils are only moderately 
reduced in IL-5–deficient mice, which are incapable of develop-
ing eosinophilia when infected with helminths or challenged with 
allergens (52, 74). Also in accordance with our results, a popula-
tion of subepithelial rEos has been shown to still be present in the 
uterus of IL-5–deficient mice. All these observations are consis-
tent with a model in which blood rEos-like eosinophils are pro-
duced by default in the absence of IL-5. These IL-5–independent 
eosinophils, although terminally differentiated, display an imma-
ture phenotype and rapidly home to the tissues where they exert 
homeostatic functions. In this model, IL-5 acts as an emergency 
cytokine that amplifies the production of eosinophils and skews 
most of the newly generated eosinophils toward the inflammato-
ry phenotype. These iEos, which have a more mature phenotype, 
are then recruited to the sites of Th2 cell responses (71, 72), where 
they participate in the elimination of extracellular parasites and 
the exacerbation of inflammation. The eosinophils that are not 
directed to the inflammatory phenotype upon IL-5 stimulation 
contribute to the maintenance of the pool of homeostatic eosino-
phils. Such a model, if applicable to humans, could further explain 
why residual eosinophils are found in the lung (75), duodenal 
mucosa (76), or blood (77, 78) of eosinophilic patients treated with 
humanized α–IL-5 Abs (75–78).
Under basal conditions, most eosinophils reside in the tissue 
where they exert key homeostatic functions (1, 2, 8, 16). Microar-
ray analyses revealed that lung rEos specifically expressed sev-
eral genes, such as Anxa1 (46), Nedd4 (47), Runx3 (48), Serpinb1a 
(49), and Ldlr (50), that are involved in the maintenance of lung 
immune homeostasis. Some of these genes are implicated in the 
Figure 8. Localization, morphology, and phenotype of lung rEos and iEos in humans. (A) Representative Congo red– and MBP-stained lung sections of 
healthy human donors and asthmatic patients. Arrows indicate Congo red– and MBP-positive eosinophils, respectively. (B) Quantification of parenchy-
mal and peribronchial eosinophils in Congo red–stained lung sections. Eos, eosinophils. (C–E) Parenchymal eosinophils from normal lung tissue (rEos) 
and eosinophils from the sputa of eosinophilic asthmatic patients (iEos) were analyzed morphologically and phenotypically. (C) Dot plots of living singlet 
CD45+SSChi cells according to surface Siglec-8 and CD125 expression. Insets depict a representative photograph of FACS-sorted rEos and iEos. (D) Repre-
sentative flow cytometric histograms of Siglec-8, CD62L, CD101, and IL-3R expression on rEos and iEos. (E) Quantification of Siglec-8, CD62L, CD101, and 
IL-3R expression levels on the surface of rEos and iEos, expressed as the FC increase in MFI as compared with the control MFI. Number are the P values 
for comparisons that were not significant (P > 0.05). (B and E) Data shown represent the mean ± SEM as well as individual values. Each dot represents 
a single individual analyzed (n = 5–8/group) (see also Supplemental Methods and Supplemental Tables 1–3). *P <0.05 and **P < 0.01, by nonparametric 
Mann-Whitney U test. Scale bars: 10 μm and 2 μm (insets in A).
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Methods
Mice. WT CD45.2 C57BL/6J, WT BALB/c, and ΔdblGATA (C.Cg-Ga-
ta1tm6Sho/J) mice were purchased from The Jackson Laboratory. All 
mice were housed and bred in institutional specific pathogen–free 
facilities. Age-matched females were used at 6 to 10 weeks of age, 
unless otherwise indicated.
Reagents. Lyophilized HDM (Dermatophagoides farinae) extracts 
were from Greer Laboratories. Grade III and grade V OVA were from 
Sigma-Aldrich. α–IL-5–neutralizing Abs (clone TRFK5; BD Bioscienc-
es) or control isotype Abs (rat IgG1) were from BD Biosciences. Details 
regarding additional reagents can be found in the respective sections 
below and in the Supplemental Methods.
Cell isolation, stainings, and flow cytometry. To obtain single 
lung cell suspensions, lungs were perfused with 10 ml PBS through 
the right ventricle, cut into small pieces, and digested for 1 hour at 
37°C in HBSS containing 1 mg/ml collagenase A (Roche) and 0.05 
mg/ml DNase I (Roche).
Staining reactions were performed at 4°C after incubation with 
2.4G2 Fc receptor Abs to reduce nonspecific binding. Cell pheno-
typing and cell sorting were performed on a FACSAria III (BD Bio-
sciences). Results were analyzed with FlowJo software (Tree Star). 
Additional details can be found in the Supplemental Methods.
Cytologic examination. Cytologic examination of FACS-sorted 
cell populations was performed on cytospin preparations stained 
with Hemacolor (Merck KGaA). Sections were examined with a 
BX45 microscope (Olympus), and photographs were taken with a 
U30 camera (Olympus).
Phagocytic activity. Naive C57BL/6 mice were injected i.t. with 50 
μl of 10% (v/v) 0.5 µm fluorescent beads. Six hours later, blood cells, 
cells from the perfusion liquid of the lung vasculature, and single lung 
cell suspensions were obtained and analyzed by flow cytometry or 
confocal microscopy (Leica SP5). Additional details can be found in 
the Supplemental Methods.
Lung histology and IHC. Methodological details regarding sample pro-
cessing, histology, and IHC are described in the Supplemental Methods.
HDM-induced airway allergy. Lightly isoflurane-anesthetized WT 
C57BL/6 mice received an i.n. instillation of vehicle (LPS-free saline) 
or HDM (100 μg in 50 μl) on days 0, 7, and 14. Mice were sacrificed on 
day 17, and the BALF and lung cells were analyzed.
Microarray data. Microarray data have been deposited in the Array 
Express public database under accession number E-MTAB-4084 
(http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4084).
In vivo α–IL-5 treatment. Numbers and phenotype of blood and 
lung eosinophil subsets from α–IL-5–treated (100 μg i.p.) naive and 
allergic C57BL/6 mice were analyzed as described in Figure 6A. 
Additional details can be found in the Supplemental Methods.
HDM-induced sensitization and restimulation of LN cells. Briefly, 
ΔdblGATA or WT control BALB/c mice received an i.n. instillation 
of saline or 5 μg HDM on day 0. Five days later, MLN cells were 
cultured in vitro for 3 days with or without HDM (30 μg/ml). The 
proliferation was measured as [3H]thymidine incorporation during 
the last 16 hours of a 3-day culture, and culture supernatants were 
assayed for cytokine production by ELISA (eBioscience). Additional 
details can be found in the Supplemental Methods.
Coculture experiments and Th2 sensitization induced by i.t. adminis-
tration of OVALPS-pulsed BMDCs. Methodological details can be found 
in the Supplemental Methods.
DCs to induce a Th2 response. Importantly, this effect was spe-
cific for rEos, as iEos were not able to inhibit the maturation and 
pro-Th2 function of DCs. Although microarray analyses provid-
ed some clues as to how rEos may regulate DC function at the 
molecular level, further investigations will be needed to eluci-
date these mechanisms.
Our analyses of small Int Eos, the largest population of 
steady-state eosinophils (26), supported the idea that these cells 
are phenotypically and functionally different from lung rEos. 
First, Int Eos, unlike rEos, did not express CD62L. Second, they 
were not able to inhibit DC maturation in vitro and even tended 
to promote such maturation, concordant with the observations 
from a previous report (14). Third, while Int Eos have been shown 
to regulate IgA+ plasma cells in the gut (17), our data showed that 
rEos did not influence the numbers of plasma cells in the lung. 
These results are consistent with the idea that the tissue micro-
environment can shape the phenotype and function of rEos 
according to the specific needs of each organ.
In humans, lung parenchymal eosinophils have rarely been 
evaluated, although some studies indicate the presence of eosin-
ophils in distal and parenchymal lung sites (81–83) in asthmatic 
patients (81, 82), but also in healthy subjects (81, 83). As superfi-
cial airways are more easily accessible than are distal lung sites 
for diagnostic purposes, it is not surprising that there has been 
a bias in focusing mainly on inflammatory airway eosinophils 
from endobronchial biopsies and BALF, rather than on parenchy-
mal eosinophils. The present study confirmed previous studies 
showing that eosinophils were present in the lung parenchyma 
of healthy humans. Though based on a limited number of sub-
jects analyzed, our data also showed that such parenchymal 
eosinophils were not more numerous in the lungs of asthmatic 
patients, in which peribronchial eosinophils were also found. 
We thus speculate that lung parenchymal eosinophils actually 
“reside” in the normal lung and represent the human counter-
part of mouse rEos. Further supporting this, we have shown that 
human rEos expressed variable levels of CD62L, as opposed to 
sputum eosinophils from asthmatic patients, which were found 
to be negative for CD62L. Last, but not least, we identified IL-3R 
as a surface marker highly expressed on such iEos. One limita-
tion of the present study is that sputum induction and process-
ing may have modified some parameters of iEos. A better com-
parator of eosinophils from normal lung tissue would have been 
eosinophils from lung tissue of asthmatic patients, which would 
have been expected to contain both Siglec-8+CD62L+IL-3Rlo rEos 
and Siglec-8+CD62LloIL-3Rhi iEos. Unfortunately, such material 
was not available. Nevertheless, our data suggest the existence of 
at least 2 phenotypically distinct eosinophil subsets in the human 
lung, i.e., a lung-resident parenchymal subset found in the nor-
mal lung and an inflammatory subset recruited to the airways 
during allergic inflammation. Whether rEos exerts immunosup-
pressive function in humans remains to be determined and rep-
resents an exciting question for future research.
In conclusion, our results indicate that lung rEos are not mere-
ly immature cells, but represent a positionally and phenotypically 
distinct eosinophil subset that participates in the fine tuning of 
respiratory immune responses by preventing Th2 responses to low 
doses of allergens, at least in mice.
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